HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, Aug. 9 (HealthDay News) -- There appears to be an inverse relationship between elevated allergy biomarker levels (immunoglobulin E [IgE]) and the risk of developing glioma, which is detectable many years before tumor diagnosis, according to a study published online Aug. 1 in the Journal of the National Cancer Institute.
Judith Schwartzbaum, Ph.D., from The Ohio State University in Columbus, and colleagues conducted a nested case-control study using serum specimens from the Janus Serum Bank cohort in Norway to assess the correlation between IgE and risk of glioma. Cases included 594 blood donors who were subsequently diagnosed with glioma (1974 through 2007); they were matched to 1,177 controls for date of blood collection, two-year age interval at blood collection, and sex. Fluorescent assays were used to measure respiratory allergen-specific and total IgE levels in the serum.
The researchers found that, among women, testing positive for allergen-specific IgE (>0.35 kUA/L) correlated with a reduced risk of glioblastoma, compared to testing negative (≤0.35 kUA/L; odds ratio [OR], 0.46). The association persisted among both sexes combined, with an OR of 0.75 for developing glioma for those testing positive for total IgE (>100 kU/L) compared with testing negative. There was a borderline statistically significantly decreased risk of glioblastoma and glioma for those simultaneously testing positive for allergen-specific IgE and total IgE, compared with simultaneously testing negative for these types of IgE. The risk of glioma was decreased for those who tested positive for total IgE at least 20 years before diagnosis, compared to those testing negative (OR, 0.54).
"Our most important finding is that testing positive for total IgE was associated with decreased glioblastoma and glioma risk at least 20 years before diagnosis," the authors write. "This observation suggests that previously reported case-control associations between allergy and glioma may not be a consequence of immune suppression resulting from the preclinical tumor."
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on June 04, 2022